EWTX - CIK 0001710072
Edgewise Therapeutics, Inc. (EWTX) reported net income of -$167.79K for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$167.79K | -25.4% |
| FY 2024 | -$133.81K | -33.6% |
| FY 2023 | -$100.16K | +99.9% |
| FY 2022 | -$67.64M | -58.0% |
| FY 2021 | -$42.81M | -150.0% |
| FY 2020 | -$17.12M | - |
Edgewise Therapeutics, Inc. (EWTX) reported net income of -$167.79K for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Edgewise Therapeutics, Inc.'s net income grew from -$17.12M to -$167.79K.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.